NeuBase Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc. is a US-based biotechnology company listed on the NASDAQ market in the United States. For French-speaking investors, the company should be viewed as a highly specialized, science-driven small-cap biotech whose historical strategy has focused on precision genetic medicines designed to modulate disease at the genetic root cause. NeuBase was founded in 2009 and is headquartered in Pittsburgh, Pennsylvania. Its core technology has centered on a proprietary peptide-nucleic acid antisense platform called PATrOL™, intended to “drug the genome” through highly targeted genetic intervention. From an operating perspective, NeuBase has historically been positioned as a preclinical development company rather than a commercial-stage drug maker. Its lead therapeutic focus has been myotonic dystrophy type 1 (DM1), where the company has reported preclinical work aimed at demonstrating broad tissue distribution, target engagement, and the potential for a whole-body treatment approach. The company has also described its platform as potentially extensible to additional genetic disease indications, which means the investment case has been built around platform optionality rather than around a diversified marketed product portfolio. At this stage, NeuBase remains a development-stage biotechnology company with no meaningful commercial revenue base and a continuing reliance on external financing. In competitive terms, NeuBase operates in an extremely crowded field that includes antisense oligonucleotides, gene modulation, and precision genetic medicine programs developed by larger, better-capitalized pharmaceutical and biotechnology peers. The company’s differentiation has been based on its PNA chemistry and the promise of targeting disease at the genetic source, but the competitive bar in this space is high, and investors generally require strong preclinical and clinical validation before assigning material long-term value. As a result, the stock has an elevated risk profile, with valuation driven primarily by scientific milestones, capital availability, and regulatory progress. Recent corporate developments are especially important. In 2024, NeuBase disclosed that it had fallen out of compliance with certain NASDAQ listing requirements following a delayed annual report filing. The company then announced that its board had approved a plan to dissolve and liquidate the company, subject to required approvals and implementation steps. That context is critical for interpreting any SEC Form 4 insider transaction activity: the equity story is no longer a standard growth-biotech narrative, but rather one dominated by restructuring, wind-down considerations, and any remaining asset-value realization.